OverviewSuggest Edit

Johnson & Johnson is a global holding company that engages in the research and development, manufacture and sale of a range of products in the healthcare field. The company operates in three business segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes a broad range of products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets. The Pharmaceutical segment is focused on the therapeutic areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolism, as well as pulmonary hypertension. The Medical Devices segment includes a broad range of products used in the orthopedic, surgery, interventional solutions, and eye health fields.

Its major brands include:

TypePublic
Founded1886
HQNew Brunswick, US
Websitejnj.com
Employee Ratings4.1
Overall CultureA-

Latest Updates

Employees (est.) (Dec 2019)132,200(-2%)
Job Openings1,458
Revenue (FY, 2019)$82.1 B
Share Price (Nov 2020)$149.9 (+2%)
Cybersecurity ratingCMore

Key People/Management at Johnson & Johnson

Alex Gorsky

Alex Gorsky

Chairman, Board of Directors and Chief Executive Officer
Joaquin Duato

Joaquin Duato

Vice Chairman of the Executive Committee
Peter Fasolo

Peter Fasolo

Executive Vice President, Chief Human Resources Officer
Ashley McEvoy

Ashley McEvoy

Executive Vice President, Worldwide Chairman, Medical Devices
Thibaut Mongon

Thibaut Mongon

Executive Vice President, Worldwide Chairman, Consumer Health
Paul Stoffels

Paul Stoffels

Vice Chairman of the Executive Committee and Chief Scientific Officer
Show more

Johnson & Johnson Office Locations

Johnson & Johnson has offices in New Brunswick, Jacksonville, Lancaster, Piscataway and in 65 other locations
New Brunswick, US (HQ)
1 Johnson And Johnson Plaza
Jacksonville, US
7500 Centurion Pkwy N
Lancaster, US
1838 Colonial Village Ln
Piscataway, US
425 NJ-18
Buenos Aires, AR
Mendoza 1259
Chippendale, AU
5 Broadway
Show all (72)

Johnson & Johnson Financials and Metrics

Johnson & Johnson Revenue

Embed Graph
View revenue for all periods
Johnson & Johnson's revenue was reported to be $82.06 b in FY, 2019 which is a 0.6% increase from the previous period.
USD

Revenue (Q2, 2020)

18.3b

Gross profit (Q2, 2020)

11.8b

Gross profit margin (Q2, 2020), %

64.1%

Net income (Q2, 2020)

3.6b

Market capitalization (13-Nov-2020)

394.6b

Closing stock price (13-Nov-2020)

149.9

Cash (28-Jun-2020)

11.2b

EV

413.8b
Johnson & Johnson's current market capitalization is $394.6 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

76.5b81.6b82.1b

Revenue growth, %

6%7%1%

Cost of goods sold

25.4b27.1b27.6b

Gross profit

51.1b54.5b54.5b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

17.8b18.8b19.7b20.0b20.8b20.3b20.0b20.6b20.7b20.7b18.3b

Cost of goods sold

5.4b5.8b6.9b6.6b6.9b6.6b6.6b6.9b6.9b7.1b6.6b

Gross profit

12.4b13.0b12.7b13.4b13.9b13.8b13.4b13.6b13.9b13.6b11.8b

Gross profit Margin, %

70%69%65%67%67%68%67%66%67%66%64%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

17.8b18.1b17.3b

Accounts Receivable

13.5b14.1b14.5b

Prepaid Expenses

2.5b2.7b2.4b

Inventories

8.8b8.6b9.0b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

20.9b12.6b15.7b14.6b17.6b16.1b14.7b14.4b16.2b15.5b11.2b

Accounts Receivable

12.3b13.3b13.2b14.2b14.1b14.0b14.1b14.7b14.8b14.9b14.6b

Prepaid Expenses

2.8b3.0b2.9b2.6b2.6b2.9b2.6b2.4b2.2b2.4b2.6b

Inventories

8.9b9.7b9.5b9.0b8.8b8.7b9.1b9.3b9.2b8.9b9.4b
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

1.3b15.3b15.1b

Depreciation and Amortization

5.6b6.9b7.0b

Inventories

581.0m(644.0m)(277.0m)

Accounts Payable

2.7b4.0b4.1b
Quarterly
USDQ1, 2018

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2.1 x
Show all financial metrics

Johnson & Johnson Operating Metrics

FY, 2016FY, 2017Jun, 2018FY, 2018FY, 2019

Manufacturing Facilities

119 125 111 97

Countries

60 60 60

Distribution Centers

350

Suppliers

3.50 k
Show all operating metrics

Johnson & Johnson Acquisitions / Subsidiaries

Company NameDateDeal Size
Momenta PharmaceuticalsAugust 19, 2020$6.50 b
TARIS BiomedicalDecember 20, 2019
Verb SurgicalDecember 20, 2019
Auris HealthJanuary 23, 2019$3.40 b
Ci:z HoldingsOctober 23, 2018$2.10 b
Zarbee's NaturalsJuly 27, 2018
OrthotaxyFebruary 20, 2018
Actelion PharmaceuticalsJanuary 26, 2017$30 b
Abott Medical OpticsSeptember 16, 2016$4.33 b
Vogue InternationalJune 02, 2016$3.30 b
Show more

Johnson & Johnson Revenue Breakdown

Embed Graph

Johnson & Johnson revenue breakdown by business segment: 31.6% from Medical Devices, 51.4% from Pharmaceutical and 16.9% from Consumer

Johnson & Johnson revenue breakdown by geographic segment: 19.0% from Asia-Pacific, Africa, 7.2% from Western Hemisphere excluding US, 22.5% from Europe and 51.3% from United States

Human Capital Metrics

Embed Graph
Show all human capital metrics

Johnson & Johnson Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

Johnson & Johnson Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Johnson & Johnson Online and Social Media Presence

Embed Graph

Johnson & Johnson Company Culture

  • Overall Culture

    A-

    74/100

  • CEO Rating

    A

    76/100

  • Compensation

    B+

    74/100

  • Diversity

    A+

    79/100

Learn more on Comparably

Johnson & Johnson News and Updates

Medical Equipment Maintenance Market is Growing CAGR of 10.45% (USD 70.87 billion) by 2027 | Biggest Innovation to Boost Global Growth, Challenge, Recent Initiatives and Business Opportunities | Major Player includes Stryker, Boston Scientific, Medtronic, Johnson & Johnson, Abbott

ENGLAND, United Kingdom, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Global Medical Equipment Maintenance Market document is composed of myriad of factors that have an influence on the market and include industry insight and critical success factors (CSFs), market segmentation and value chain analysis, indu…

North America Vaccines Market to Witness an Outstanding Growth During 2020 With Top Key Players PFIZER INC, GlaxoSmithKline plc., Sanofi, Johnson & Johnson Services, Inc

The North America vaccines market is expected to reach US$ 24,510.0 Mn in 2027 from US$ 14,566.0 Mn in 2018. The market is estimated to grow with a CAGR of 6.0% from 2019-2027. Posted via Industry Today. Follow us on Twitter @IndustryToday

Johnson & Johnson Stock Looks Attractive At $145

Johnson & Johnson’s stock lost more than 23% – dropping from $146 at the beginning of the year to below $112 in late March – then spiked 30% to around $145 now. That means it has fully recovered to the levels where it started the year. Why? While the Covid-19 outbreak and associated lockdowns...

What The Pause In The Johnson & Johnson And Eli Lilly Covid Drug Trials May Mean

Rushing toward approval of Covid vaccines and treatments—while understandable—can be dangerous.

Connected Medical Devices 2020 Global Market Key Players – Medtronic, GE Healthcare, Johnson & Johnson, Omron - Analysis and Forecast to 2026

Wiseguyreports.Com Publish New Market Research Report On-“Connected Medical Devices Market 2020 Global Analysis, Size, Share, Trends, Opportunities and Growth, Forecast 2026” Posted via Industry Today. Follow us on Twitter @IndustryToday

Johnson & Johnson falls despite earnings beat after pausing COVID-19 vaccine trial due to unexpected illness (JNJ)

Summary List Placement Johnson & Johnson fell as much as 3% on Tuesday after it temporarily paused its COVID-19 vaccine trial due to an "unexpected illness" in a trial participant.  "Adverse events – illnesses, accidents, etc. – even those that are serious, are an expected part of any clinical…
Show more

Johnson & Johnson Blogs

European Commission Approves Janssen’s TREMFYA®▼ (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)

European Commission Approves Janssen’s TREMFYA®▼ (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA) Liz.McPherson@… Tue, 12/01/2020 - 08:53 European Commission Approves Janssen’s TREMFYA®▼ (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (P…

Janssen Submits Applications in U.S. and EU Seeking Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)/DARZALEX® (daratumumab) Subcutaneous (SC) Formulation in Combination With Pomalidomide and Dexamethasone for Patients With Relapsed or Re

Janssen Submits Applications in U.S. and EU Seeking Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)/DARZALEX® (daratumumab) Subcutaneous (SC) Formulation in Combination With Pomalidomide and Dexamethasone for Patients With Relapsed or Re Liz.McPherson@… Thu, 11/12/2020 - 09:46 …

New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020

New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020 Liz.McPherson@… Mon, 11/09/2020 - 09:13 New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) Data from E…

Johnson & Johnson to Host Virtual Medical Devices Update

Johnson & Johnson to Host Virtual Medical Devices Update Brian.Hoenig@n… Fri, 11/06/2020 - 08:31 Johnson & Johnson to Host Virtual Medical Devices Update Nov 06, 2020 This release is a backfill from a News Wire N…

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio Liz.McPherson@… Thu, 11/05/2020 - 07:40 Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations…

Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supplemental New Drug Application to U.S. FDA for Treatment of Schizophrenia in Adults

Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supplemental New Drug Application to U.S. FDA for Treatment of Schizophrenia in Adults Liz.McPherson@… Mon, 11/02/2020 - 07:54 Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supplemental New Drug Application to U.S. FDA for Treat…
Show more

Johnson & Johnson Frequently Asked Questions

  • When was Johnson & Johnson founded?

    Johnson & Johnson was founded in 1886.

  • Who are Johnson & Johnson key executives?

    Johnson & Johnson's key executives are Alex Gorsky, Joaquin Duato and Peter Fasolo.

  • How many employees does Johnson & Johnson have?

    Johnson & Johnson has 132,200 employees.

  • What is Johnson & Johnson revenue?

    Latest Johnson & Johnson annual revenue is $82.1 b.

  • What is Johnson & Johnson revenue per employee?

    Latest Johnson & Johnson revenue per employee is $620.7 k.

  • Who are Johnson & Johnson competitors?

    Competitors of Johnson & Johnson include Bayer, Pfizer and Procter & Gamble.

  • Where is Johnson & Johnson headquarters?

    Johnson & Johnson headquarters is located at 1 Johnson And Johnson Plaza, New Brunswick.

  • Where are Johnson & Johnson offices?

    Johnson & Johnson has offices in New Brunswick, Jacksonville, Lancaster, Piscataway and in 65 other locations.

  • How many offices does Johnson & Johnson have?

    Johnson & Johnson has 72 offices.